source
- Novartis halts CD19 CAR-T trial after three deaths, Bristol Myers also pauses similar programNovartis announced a pause to its CD19-directed CAR-T cell therapy trials after three patients experienced fatal immune reactions. The company said the deaths were linked to a severe cytokine relea…
- Novartis and BMS pause CAR-T trials after fatal immune syndrome casesNovartis has halted several immunology and neurology studies of its CAR T candidate rapcabtagene autoleucel after three patients experienced fatal immune effector cell‑associated hemophagocytic syn…